國家衛生研究院 NHRI:Item 3990099045/4446
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 912405      線上人數 : 1175
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4446


    題名: Abrogation of skin disease in lupus-prone MRL/Fas(lpr) mice by means of a novel tylophorine analog
    作者: Choi, JY;Gao, WL;Odegard, J;Shiah, HS;Kashgarian, M;McNiff, JM;Baker, DC;Cheng, YC;Craft, J
    貢獻者: National Institute of Cancer Research
    摘要: Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-kappa B, on end-organ disease in the MRL-Fas(lpr) murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRL/Fas(lpr) mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclophosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, bracbial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas(lpr) mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Fas(lpr) mice responds differentially to NF-kappa B inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MRL/Fas(lpr) mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.
    日期: 2006-10
    關聯: Arthritis and Rheumatism. 2006 Oct;54(10):3277-3283.
    Link to: http://dx.doi.org/10.1002/art.22119
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000241260800027
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33750345392
    顯示於類別:[夏和雄(1996-2012)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000241260800027.pdf483KbAdobe PDF947檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋